金年会jinnian

The Microdiag Big Health Division is committed to screening major chronic diseases such as tumors and liver damage, providing "high-risk group" screening services from healthy individuals to disease populations. By deeply cultivating private chain physical examinations and chain clinical examination channels for special inspections, we aim to select innovative products and achieve full channel development of toB and toC.

Currently operating a testing product with NMPA approval: the new colon cancer label "Wei Changwei" ®” CST4, New Molecular Indicator for Colon Cancer Blood Test "Chang Jiu'an ®” Septin9, a new indicator for pan cancer screening, "Dopplectra" DR-70. As well as the new index sH2a of liver disease screening, lung screening product "clear lung", multi tumor liquid biopsy ultra early screening "preMeD", AD, bladder cancer cancer, prostate cancer, cervical cancer and other innovative screening products.

Relying on cutting-edge scientific research capabilities and numerous technological reserves, we have formed a product line for screening major chronic diseases such as tumors and liver damage, in order to meet the needs of different markets.

At present, the business has covered areas such as the Yangtze River Delta, Pearl River Delta, and Beijing Tianjin Hebei. The diversification of our product structure enables us to serve a wider and more diverse customer base. We will adhere to our mission of providing innovative screening solutions for major disease warnings, and continuously strive to become a leading brand in major chronic disease screening fields such as early screening of tumors and liver and kidney injuries. Our goal is to enable our customers to "afford and enjoy" the highest quality products and services.